Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells

Pancreatology

Volumn 10, Issue 5, 2010, Pages 565-579

  Gupta, Seema ^a,b   Sathishkumar, Sabapathi ^c   Ahmed, Mansoor M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cell cycle arrest; Mismatch repair; p21; p53; Pancreatic cancer; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DRUG ACTIVITY; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MISMATCH REPAIR; MITOSIS INDEX; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; WESTERN BLOTTING;

EID: 77958514284     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000317254     Document Type: Article

References (52)

1. Lowenfels AB, Maisonneuve P: Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004; 34: 238-244.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
3. Hennig R, Ding XZ, Adrian TE: On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 2004; 19: 999-1011.
4. Diaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, Baselga J: Capecitabine (xeloda) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13: 558-565.
5. Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
6. Diaz-Rubio E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 2004; 9: 282-294.
7. Oster MW, Gray R, Panasci L, Perry MC: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57: 29-33.
8. Hilgers W, Kern SE: Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 1999; 26: 1-12.
9. Frey C, Twomey P, Keehn R, Elliott D, Higgins G: Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981; 47: 27-31.
10. Kokkinakis DM, Ahmed MM, Delgado R, Fruitwala MM, Mohiuddin M, Albores-Saavedra J: Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res 1997; 57: 5360-5368.
11. Kokkinakis DM, Ahmed MM, Chendil D, Moschel RC, Pegg AE: Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine. Clin Cancer Res 2003; 9: 3801-3807.
12. Preuss I, Thust R, Kaina B: Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer 1996; 65: 506-512.
13. Karran P, Stephenson C: Mismatch binding proteins and tolerance to alkylating agents in human cells. Mutat Res 1990; 236: 269-275.
14. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P: An alkylation-tolerant, mutator human cell line is deficient in strandspecific mismatch repair. Proc Natl Acad Sci USA 1993; 90: 6424-6428.
15. Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, Modrich P: Human mutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4methylthymine, or the cisplatind( GpG) adduct. Proc Natl Acad Sci USA 1996; 93: 6443-6447.
16. Yamane K, Taylor K, Kinsella TJ: Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-chk1 pathway. Biochem Biophys Res Commun 2004; 318: 297-302.
17. Dodson GE, Shi Y, Tibbetts RS: DNA replication defects, spontaneous DNA damage, and ATM-dependent checkpoint activation in replication protein A-deficient cells. J Biol Chem 2004; 279: 34010-34014.
18. Yan T, Desai AB, Jacobberger JW, Sramkoski RM, Loh T, Kinsella TJ: CHK1 and CHK2 are differentially involved in mismatch repairmediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 2004; 3: 1147-1157.
19. O'Connor PM, Fan S: DNA damage checkpoints: implications for cancer therapy. Prog Cell Cycle Res 1996; 2: 165-173.
20. Weinert TA, Kiser GL, Hartwell LH: Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes Dev 1994; 8: 652-665.
21. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y: Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001; 61: 8211-8217.
22. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A: An indolocarbazole inhibitor of human checkpoint kinase (chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000; 60: 566-572.
23. Hirose Y, Berger MS, Pieper RO: P53 affects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001; 61: 1957-1963.
24. Li X, Ding X, Adrian TE: Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004; 22: 389-400.
25. Shukla S, Gupta S: Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 2004; 39: 114-126.
26. Giannakakou P, Robey R, Fojo T, Blagosklonny MV: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/ G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001; 20: 3806-3813.
27. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8: 2725-2734.
28. Escobedo J, Koh TJ: Improved transfection technique for adherent cells using a commercial lipid reagent. Biotechniques 2003; 35: 936-938, 940.
29. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM: Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002; 1: 152-160.
30. Ahmed MM, Sells SF, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Harp C, Mohiuddin M, Rangnekar VM: Ionizing radiation- inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J Biol Chem 1997; 272: 33056-33061.
31. Kaina B, Christmann M: DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 2002; 40: 354-367.
32. Meikrantz W, Bergom MA, Memisoglu A, Samson L: O6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis 1998; 19: 369-372.
33. Kaina B, Ziouta A, Ochs K, Coquerelle T: Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 1997; 381: 227-241.
34. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
35. Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-2196.
36. Khanna KK, Lavin MF, Jackson SP, Mulhern TD: ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 2001; 8: 1052-1065.
37. Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-168.
38. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K, Savage K, Lukas J, Zhou BB, Bartek J, Khanna KK: Ataxia-telangiectasia- mutated (ATM) and nbs1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003; 278: 14806-14811.
39. Rhind N, Russell P: Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J Cell Sci 2000; 113: 3889-3896.
40. Bartek J, Lukas J: Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001; 490: 117-122.
41. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54: 334-341.
42. Duckett DR, Bronstein SM, Taya Y, Modrich P: HmutSalpha-and hmutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci USA 1999; 96: 12384-12388. (Pubitemid 29513511)
43. Hickman MJ, Samson LD: Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 1999; 96: 10764-10769.
44. Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, Baskaran R: The mismatch repair system is required for Sphase checkpoint activation. Nat Genet 2003; 33: 80-84.
45. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO: The p38 mitogen- activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 2003; 23: 8306-8315.
46. Wang H, Yang Y, Schofield MJ, Du C, Fridman Y, Lee SD, Larson ED, Drummond JT, Alani E, Hsieh P, Erie DA: DNA bending and unbending by MutS govern mismatch recognition and specificity. Proc Natl Acad Sci USA 2003; 100: 14822-14827.
47. Kim HS, Cho HJ, Park SJ, Park KW, Chae IH, Oh BH, Park YB, Lee MM: The essential role of p21 in radiation-induced cell cycle arrest of vascular smooth muscle cell. J Mol Cell Cardiol 2004; 37: 871-880.
48. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ: Clustering-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 2004; 64: 7412-7419.
49. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC: Phosphorylation/ cytoplasmic localization of p21Cip1/ WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004; 10: 3815-3824.
50. Lee S, Helfman DM: Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem 2004; 279: 1885-1891.
51. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, D'Atri S: DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 2004; 66: 478-491.
52. Hirose Y, Katayama M, Berger MS, Pieper RO: Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg 2004; 100: 1060-1065.